Our webinar for potential applicants of the Advancing Treatment Award is now available for you to watch!

The webinar provided information and tips on how to develop a successful application. We heard from Ang Armstrong, affected by MND, Jessica Lee, our Director of Research, Dr Richard Mead and Dr Jill Richardson, respectively Chair and Vice-Chair of the MN5DF Research Review Committee (RRC). They shared their perspectives and insights with the community.

Our Chair and Vice-Chair of the RRC discussed the critical aspects of validating therapeutic targets in MND research. They emphasised the importance of using robust and relevant models and the need for a clear demonstration of target engagement and pathway modulation. Ang Armstrong emphasised the need for accessible lay summaries to ensure that research proposals are understandable to those without a scientific background, which impacts funding decisions.

Our budget for the Advancing Treatments Award 2024 is £1.75 million, we invite researchers not to miss this opportunity and submit their applications before midday on the 17th of May.

Watch here.

More news & stories

View all
 picture
Research
23 Sep 2026

Topline announcement of Phase 3 trial results for FUS-MND appear promising

Yesterday, the companies Otsuka and Ionis announced the results of their Phase 3 trial of the genetic therapy, ulefnersen. Ulefnersen targets a rare form of MND…
Read more
 picture
MND stories Research
14 Sep 2026

R.A.C.E. to Diagnose: New training programme to speed up MND diagnosis

For Andy Vaughton, receiving a motor neuron disease (MND) diagnosis in 2021 finally provided an answer for symptoms he had been struggling with for several years.…
Read more
 picture
Fundraising MND stories
10 Sep 2026

"I love you, and this is for you": Cammy cycles over 1,000 miles in memory of his Dad

This year, Cammy Jones has taken on two long-distance cycling challenges for My Name’5 Doddie Foundation: Doddie’s Triple Crown, which saw him ride from Melrose…
Read more
Bell icon

Join our Newsletter!

By subscribing, you confirm that you agree with our terms and conditions.